The Centers for Medicare and Medicaid Services (CMS) announced this week that it would expand coverage for PET scans used in the diagnosis of Alzheimer's disease.
CMS has been hesitant to open reimbursements for the procedure, and the agency has long said that it would only cover one brain scan per beneficiary for a patient's...Arizona News
The event is designed to help families and providers better understand the impact dementia may have on tribal communities. The conference is scheduled in Tucson from 8:30 a.m. to 3:30 p.m. on Oct 19, at Desert Diamond Casinos.
According to the Alzheimer’s Association, Native Americans are more likely to develop the disease or other...National News
Support for Medicare coverage of the anti-Alzheimer's drug Leqembi is growing on Capitol Hill, but estimates of the drug's cost may prove to be prohibitive for the Medicare program.
Coverage of the drug through the Medicare program would raise costs for the program by $2 billion to $5 billion per year, according to a new study by...National News
As pressure mounts from stakeholders and lawmakers, Eli Lilly, producer of the experimental Alzheimer's antibody drug donanemab, is saying that it expects the Centers for Medicare and Medicaid Services (CMS) to reverse its prohibition of anti-amyloids.
A bipartisan group of nearly half of U.S. state attorneys general sent a letter to...National News
Despite the Centers for Medicare and Medicaid Services’ (CMS) efforts to reduce the amount of psychotropic drugs in nursing homes, rates remained “constant” between 2011 and 2019.
A new report from the Department of Health and Human Services (HHS) Office of Inspector General (OIG) found 80% of Medicare's long-stay nursing home...CMS Rules
Last Friday, the Centers for Medicare and Medicaid Services (CMS) published a report that reviewed the Medicare Supplementary Medical Insurance (SMI) Trust Fund for 2023 and determined that cost-savings from unexpectedly low Medicare Part B spending in 2022 could be recommended to drive premium cuts for Part B coverage next year.
The...
The nursing workforce shortage shows no sign of letting up, with concerns rising for providers both nationally and in Arizona. While the Occupational Health and Safety Administration (OSHA) debates efforts to intervene with workforce protections from future COVID surges, experts suggest that efforts for recruitment and retention may...
Last Monday, the Food and Drug Administration approved a breakthrough new treatment for Alzheimer's disease. The treatment is the first of its kind in decades but many in the scientific community remain skeptical of the new drug's effectiveness.
Aduhelm -- the brand name of aducanumab -- is designed to eliminate clumps of a toxic...National News
Pharmaceutical companies Eli Lilly & Co. and AstraZeneca PLC are completely scrapping trials of an experimental drug they were co-developing for the treatment of Alzheimer's. It is an unsurprising announcement among various other disappointing efforts to close the gap to the finish line in the race against the debilitating...